GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intravenous Infusions Ltd (XGHA:IIL) » Definitions » Asset Impairment Charge

Intravenous Infusions (XGHA:IIL) Asset Impairment Charge : GHS0.00 Mil (TTM As of . 20)


View and export this data going back to 2015. Start your Free Trial

What is Intravenous Infusions Asset Impairment Charge?

Intravenous Infusions's Asset Impairment Charge for the six months ended in . 20 was GHS0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in . 20 was GHS0.00 Mil.


Intravenous Infusions Asset Impairment Charge Historical Data

The historical data trend for Intravenous Infusions's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intravenous Infusions Asset Impairment Charge Chart

Intravenous Infusions Annual Data
Trend
Asset Impairment Charge

Intravenous Infusions Semi-Annual Data
Asset Impairment Charge

Intravenous Infusions Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Asset Impairment Charge for the trailing twelve months (TTM) ended in . 20 was GHS0.00 Mil.


Intravenous Infusions Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Intravenous Infusions's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.


Intravenous Infusions (XGHA:IIL) Business Description

Traded in Other Exchanges
N/A
Address
Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.